# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks prof...
Barclays analyst Gena Wang maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target f...
Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price targ...
Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the ...
Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and raises the price target fro...
2024 Full Year Financial GuidanceTotal revenue guidance increased to be in the range of $530 million to $550 million (previousl...
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimat...
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the company will share the latest clinical data, regulatory p...
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and maintains $111 price...